River BioMedics combines cardiac biology knowledge with expertise in bio-engineering and human induced pluripotent stem cells (hiPSC) to develop 3D cardiac in vitro models for the discovery and development of novel cardiac drugs.

River BioMedics

We combine our cardiac biology knowhow with our expertise in bio-engineering and human induced pluripotent stem cells (hiPSC) to develop 3D cardiac in vitro models for the discovery and development of novel cardiac drugs.

KIKK Capital

OostNL

BioGeneration Ventures

River BioMedics 

We had a great time at EUROoCS in Milan last week! Amélie BOCQUET and Chloë Kaal showcased our work in a poster session. We enjoyed the many inspiring talks and all the connections we made.

Did you miss us there? Feel free to connect now!

#closertotheheart #3Dheartmodels #drugdiscovery

We are excited to share that our CSO, Marcelo Catarino Ribeiro, will attend the Oxford Global - 3D Cell Culture and Organ Modelling 2024 conference in London next week. He'll be part of two panel discussions and will share our work on cardiac target validation:

📌 18th of March 13.40 - Panel Discussion: Validation Of Organ Models
📌 19th of March 11.40 - Panel Discussion: Overcoming Challenges Of Scalability In Organoid Modelling
📌 19th of March 12.40 - Presentation: Modeling HFpEF Cardiac Stiffness Using Human 3D Cardiac Tissues And Its Application In Target Validation

Can't make it? Check out our 3D cardiac models at RiverBioMedics.com or contact us! 

#OxfordGlobal2024 #closertotheheart #3Dheartmodels #drugdiscovery

We are proud to share our latest publication in Advanced Healthcare Materials: Micro-Engineered Heart Tissues On-Chip with Heterotypic Cell Composition Display Self-Organization and Improved Cardiac Function.

Many thanks to all those that contributed!

Discover all of our work at our website: https://lnkd.in/eghxaAXZ

#closertotheheart #3Dheartmodels #drugdiscovery

Find us at #BioEquityEurope 12-14th of May to hear more about our disease modifying approach to HFpEF and our 3D cardiac strip technology!

#closertotheheart #3Dheartmodels #drugdiscovery

We are attending EUROoCS in Milan this week (3rd-5th of July). 

Find us at the poster session on Friday (12:30-14:00):

📌 F-035 - Amélie BOCQUET - Rapid-prototyped macro-valves for fluidic control of μ3Dcardiac tissues-on-chip

📌 F-039 - Chloë Kaal - Maturation induced Titin isoform switching in 3D cardiac stiffening model

Can’t make it? Check out our 3D cardiac models at RiverBioMedics.com or contact us!

#EUROoCS2024 #closertotheheart #3Dheartmodels #drugdiscovery

Our team will be present at ELRIG UK DRUG DISCOVERY 2023 and we are very much looking forward to seeing you there. 

Our CEO, Nicky Cooper, is co-charing one of the sessions TRANSLATING IDEAS INTO THERAPIES:

"Join me in person, for free, on 18 - 19 October 2023. I'm looking forward to co-chairing a session at this meeting hosted by ELRIG UK at the at ACC, Liverpool."

#ELRIG #ELRIGDD23 #DrugDiscovery #DD2023 #networking #closertotheheart #3Dheartmodels

msh id	COM:RIVERBIOMEDICS
symbol	-
name	River BioMedics
homepage url	https://riverbiomedics.com
country	NL
sector	Healthcare & Health Services
industry	Biotechnology
market	PRIVATE
employee count	16
crunchbase url	-
linkedin url	https://www.linkedin.com/company/river-biomedics
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:RIVERBIOMEDICS

River BioMedics

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-